SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Bukhari MA, Wiles NJ, Lunt M, Harrison BJ, Scott DG, Symmons DP, et al. Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: results from a large observational inception study. Arthritis Rheum 2003; 48: 4653.
  • 2
    Landewe RB. The benefits of early treatment in rheumatoid arthritis: confounding by indication, and the issue of timing [editorial]. Arthritis Rheum 2003; 48: 15.
  • 3
    Lard LR, Visser H, Speyer I, van der Horst-Bruinsma IE, Zwinderman AH, Breedveld FC, et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am J Med 2001; 111: 44651.
  • 4
    Rantapaa-Dahlqvist S. Diagnostic and prognostic significance of autoantibodies in early rheumatoid arthritis. Scand J Rheumatol 2005; 34: 8396.
  • 5
    Kim JM, Weisman MH. When does rheumatoid arthritis begin and why do we need to know? [review]. Arthritis Rheum 2000; 43: 47384.
  • 6
    Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 2007; 146: 40615.
  • 7
    Waaler E. On the occurrence of a factor in human serum activating the specific agglutination of sheep red blood corpuscles: 1939. Acta Pathol Microbiol Scand 1940; 17: 17288.
  • 8
    Rose H. Differential agglutination of normal and sensitized sheep erythrocytes by sera of patients with rheumatoid arthritis. Proc Soc Exp Biol Med 1948; 68: 16.
  • 9
    Lee DM, Schur PH. Clinical utility of the anti-CCP assay in patients with rheumatic diseases. Ann Rheum Dis 2003; 62: 8704.
  • 10
    Bas S, Perneger TV, Seitz M, Tiercy JM, Roux-Lombard P, Guerne PA. Diagnostic tests for rheumatoid arthritis: comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin antibodies and IgM rheumatoid factors. Rheumatology (Oxford) 2002; 41: 80914.
  • 11
    Bas S, Perneger TV, Kunzle E, Vischer TL. Comparative study of different enzyme immunoassays for measurement of IgM and IgA rheumatoid factors. Ann Rheum Dis 2002; 61: 50510.
  • 12
    Prentice AG, Hickling P, Wiseman IC, Holwill CJ, Northwood J. Prospective comparison of laser nephelometry with standard agglutination techniques for detection of rheumatoid factor. J Clin Pathol 1987; 40: 21620.
  • 13
    US Food and Drug Administration. In vitro diagnostics. 2008. URL: http://www.fda.gov/cdrh/oivd/.
  • 14
    Rantapaa-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003; 48: 27419.
  • 15
    Bas S, Genevay S, Meyer O, Gabay C. Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology (Oxford) 2003; 42: 67780.
  • 16
    Jonsson T, Steinsson K, Jonsson H, Geirsson AJ, Thorsteinsson J, Valdimarsson H. Combined elevation of IgM and IgA rheumatoid factor has high diagnostic specificity for rheumatoid arthritis. Rheumatol Int 1998; 18: 11922.
  • 17
    Swedler W, Wallman J, Froelich CJ, Teodorescu M. Routine measurement of IgM, IgG, and IgA rheumatoid factors: high sensitivity, specificity, and predictive value for rheumatoid arthritis. J Rheumatol 1997; 24: 103744.
  • 18
    Van Leeuwen MA, Westra J, van Riel PL, Limburg PC, van Rijswijk MH. IgM, IgA, and IgG rheumatoid factors in early rheumatoid arthritis predictive of radiological progression? Scand J Rheumatol 1995; 24: 14653.
  • 19
    Van Leeuwen MA, Westra J, Limburg PC, de Jong HJ, Marrink J, van Rijswijk MH. Quantitation of IgM, IgA and IgG rheumatoid factors by ELISA in rheumatoid arthritis and other rheumatic disorders. Scand J Rheumatol Suppl 1988; 75: 2531.
  • 20
    Shmerling RH. Diagnostic tests for rheumatic disease: clinical utility revisited. South Med J 2005; 98: 70428.
  • 21
    Shmerling RH, Delbanco TL. The rheumatoid factor: an analysis of clinical utility. Am J Med 1991; 91: 52834.
  • 22
    Shmerling RH, Delbanco TL. How useful is the rheumatoid factor? An analysis of sensitivity, specificity, and predictive value. Arch Intern Med 1992; 152: 241720.
  • 23
    Lichtenstein MJ, Pincus T. Rheumatoid arthritis identified in population based cross sectional studies: low prevalence of rheumatoid factor. J Rheumatol 1991; 18: 98993.
  • 24
    Dorner T, Egerer K, Feist E, Burmester GR. Rheumatoid factor revisited. Curr Opin Rheumatol 2004; 16: 24653.
  • 25
    Sauerland U, Becker H, Seidel M, Schotte H, Willeke P, Schorat A, et al. Clinical utility of the anti-CCP assay: experiences with 700 patients. Ann N Y Acad Sci 2005; 1050: 3148.
  • 26
    Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S, et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 2007; 146: 797808.
  • 27
    Anuradha V, Chopra A. In the era of nephelometry, latex agglutination is still good enough to detect rheumatoid factor. J Rheumatol 2005; 32: 23434.
  • 28
    Shmerling RH. Rheumatic disease: choosing the most useful diagnostic tests. Geriatrics 1996; 51: 2232.
  • 29
    Wolfe F, Cathey MA, Roberts FK. The latex test revisited: rheumatoid factor testing in 8,287 rheumatic disease patients. Arthritis Rheum 1991; 34: 95160.
  • 30
    Nienhuis RL, Mandema E. A new serum factor in patients with rheumatoid arthritis: the antiperinuclear factor. Ann Rheum Dis 1964; 23: 3025.
  • 31
    Hoet RM, Boerbooms AM, Arends M, Ruiter DJ, van Venrooij WJ. Antiperinuclear factor, a marker autoantibody for rheumatoid arthritis: colocalisation of the perinuclear factor and profilaggrin. Ann Rheum Dis 1991; 50: 6118.
  • 32
    Young BJ, Mallya RK, Leslie RD, Clark CJ, Hamblin TJ. Anti-keratin antibodies in rheumatoid arthritis. Br Med J 1979; 2: 979.
  • 33
    Sebbag M, Simon M, Vincent C, Masson-Bessiere C, Girbal E, Durieux JJ, et al. The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. J Clin Invest 1995; 95: 26729.
  • 34
    Baeten D, Peene I, Union A, Meheus L, Sebbag M, Serre G, et al. Specific presence of intracellular citrullinated proteins in rheumatoid arthritis synovium: relevance to antifilaggrin autoantibodies. Arthritis Rheum 2001; 44: 225562.
  • 35
    Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van Venrooij WJ. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998; 101: 27381.
  • 36
    Nogueira L, Sebbag M, Vincent C, Arnaud M, Fournie B, Cantagrel A, et al. Performance of two ELISAs for antifilaggrin autoantibodies, using either affinity purified or deiminated recombinant human filaggrin, in the diagnosis of rheumatoid arthritis. Ann Rheum Dis 2001; 60: 8827.
  • 37
    Vincent C, Nogueira L, Sebbag M, Chapuy-Regaud S, Arnaud M, Letourneur O, et al. Detection of antibodies to deiminated recombinant rat filaggrin by enzyme-linked immunosorbent assay: a highly effective test for the diagnosis of rheumatoid arthritis. Arthritis Rheum 2002; 46: 20518.
  • 38
    Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000; 43: 15563.
  • 39
    Vittecoq O, Incaurgarat B, Jouen-Beades F, Legoedec J, Letourneur O, Rolland D, et al. Autoantibodies recognizing citrullinated rat filaggrin in an ELISA using citrullinated and non-citrullinated recombinant proteins as antigens are highly diagnostic for rheumatoid arthritis. Clin Exp Immunol 2004; 135: 17380.
  • 40
    Saraux A, Berthelot JM, Devauchelle V, Bendaoud B, Chales G, le Henaff C, et al. Value of antibodies to citrulline-containing peptides for diagnosing early rheumatoid arthritis. J Rheumatol 2003; 30: 25359.
  • 41
    Coenen D, Verschueren P, Westhovens R, Bossuyt X. Technical and diagnostic performance of 6 assays for the measurement of citrullinated protein/peptide antibodies in the diagnosis of rheumatoid arthritis. Clin Chem 2007; 53: 498504.
  • 42
    Correia ML, Carvalho S, Fortuna J, Pereira MH. Comparison of three anti-CCP antibody tests and rheumatoid factor in RA and control patients. Clin Rev Allergy Immunol 2008; 34: 215.
  • 43
    Santiago M, Baron M, Miyachi K, Fritzler MJ, Abu-Hakima M, Leclercq S, et al. A comparison of the frequency of antibodies to cyclic citrullinated peptides using a third generation anti-CCP assay (CCP3) in systemic sclerosis, primary biliary cirrhosis and rheumatoid arthritis. Clin Rheumatol 2008; 27: 7783.
  • 44
    Despres N, Boire G, Lopez-Longo FJ, Menard HA. The Sa system: a novel antigen-antibody system specific for rheumatoid arthritis. J Rheumatol 1994; 21: 102733.
  • 45
    Vossenaar ER, Despres N, Lapointe E, van der Heijden A, Lora M, Senshu T, et al. Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res Ther 2004; 6: R14250.
  • 46
    Goldbach-Mansky R, Lee J, McCoy A, Hoxworth J, Yarboro C, Smolen JS, et al. Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res 2000; 2: 23643.
  • 47
    Bang H, Egerer K, Gauliard A, Luthke K, Rudolph PE, Fredenhagen G, et al. Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum 2007; 56: 250311.
  • 48
    Soos L, Szekanecz Z, Szabo Z, Fekete A, Zeher M, Horvath IF, et al. Clinical evaluation of anti-mutated citrullinated vimentin by ELISA in rheumatoid arthritis. J Rheumatol 2007; 34: 165863.
  • 49
    Szekanecz Z, Soos L, Szabo Z, Fekete A, Kapitany A, Vegvari A, et al. Anti-citrullinated protein antibodies in rheumatoid arthritis: as good as it gets? Clin Rev Allergy Immunol 2008; 34: 2631.
  • 50
    Berglin E, Padyukov L, Sundin U, Hallmans G, Stenlund H, Van Venrooij WJ, et al. A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis. Arthritis Res Ther 2004; 6: R3038.
  • 51
    Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004; 50: 3806.
  • 52
    Berglin E, Johansson T, Sundin U, Jidell E, Wadell G, Hallmans G, et al. Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. Ann Rheum Dis 2006; 65: 4538.
  • 53
    Vencovsky J, Machacek S, Sedova L, Kafkova J, Gatterova J, Pesakova V, et al. Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis 2003; 62: 42730.
  • 54
    Meyer O, Labarre C, Dougados M, Goupille P, Cantagrel A, Dubois A, et al. Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 2003; 62: 1206.
  • 55
    Forslind K, Ahlmen M, Eberhardt K, Hafstrom I, Svensson B. Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis 2004; 63: 10905.
  • 56
    Quinn MA, Gough AK, Green MJ, Devlin J, Hensor EM, Greenstein A, et al. Anti-CCP antibodies measured at disease onset help identify seronegative rheumatoid arthritis and predict radiological and functional outcome. Rheumatology (Oxford) 2006; 45: 47880.
  • 57
    Del val del Amo N, Ibanez Bosch R, Fito Manteca C, Gutierrez Polo R, Loza Cortina E. Anti-cyclic citrullinated peptide antibody in rheumatoid arthritis: relation with disease aggressiveness. Clin Exp Rheumatol 2006; 24: 2816.
  • 58
    Panchagnula R, Rajiv SR, Prakash J, Chandrashekara S, Suresh KP. Role of anticyclic citrullinated peptide in the diagnosis of early rheumatoid factor-negative suspected rheumatoid arthritis: is it worthwhile to order the test? J Clin Rheumatol 2006; 12: 1725.
  • 59
    Machold KP, Stamm TA, Nell VP, Pflugbeil S, Aletaha D, Steiner G, et al. Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease. Rheumatology (Oxford) 2007; 46: 3429.
  • 60
    Majka DS, Deane KD, Parrish LA, Lazar AA, Baron AE, Walker CW, et al. Duration of preclinical rheumatoid arthritis-related autoantibody positivity increases in subjects with older age at time of disease diagnosis. Ann Rheum Dis 2008; 67: 8017.
  • 61
    Potter C, Hyrich KL, Tracey A, Lunt M, Plant D, Symmons DP, et al. Association of RF and anti-CCP positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-TNF response in RA. Ann Rheum Dis 2009; 68: 6974.
  • 62
    Snir O, Widhe M, von Spee C, Lindberg J, Padyukov L, Lundberg K, et al. Multiple antibody reactivities to citrullinated antigens in sera from rheumatoid arthritis patients: association with HLA-DRB1 alleles. Ann Rheum Dis 2009; 68: 73643.
  • 63
    Kokkonen H, Johansson M, Innala L, Jidell E, Rantapaa-Dahlqvist S. The PTPN22 1858C/T polymorphism is associated with anti-cyclic citrullinated peptide antibody-positive early rheumatoid arthritis in northern Sweden. Arthritis Res Ther 2007; 9: R56.
  • 64
    Orozco G, Pascual-Salcedo D, Lopez-Nevot MA, Cobo T, Cabezon A, Martin-Mola E, et al. Auto-antibodies, HLA and PTPN22: susceptibility markers for rheumatoid arthritis. Rheumatology (Oxford) 2008; 47: 13841.
  • 65
    Klareskog L, Stolt P, Lundberg K, Kallberg H, Bengtsson C, Grunewald J, et al, and the Epidemiological Investigation of Rheumatoid Arthritis Study Group. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA–DR (shared epitope)–restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 2006; 54: 3846.
  • 66
    Kallberg H, Padyukov L, Plenge RM, Ronnelid J, Gregersen PK, van der Helm-van Mil AH, et al. Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis. Am J Hum Genet 2007; 80: 86775.
  • 67
    Kastbom A, Strandberg G, Lindroos A, Skogh T. Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis 2004; 63: 10859.
  • 68
    Alessandri C, Bombardieri M, Papa N, Cinquini M, Magrini L, Tincani A, et al. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFα therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann Rheum Dis 2004; 63: 121821.
  • 69
    Atzeni F, Sarzi-Puttini P, Dell' Acqua D, de Portu S, Cecchini G, Cruini C, et al. Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study. Arthritis Res Ther 2006; 8: R3.
  • 70
    Bobbio-Pallavicini F, Alpini C, Caporali R, Avalle S, Bugatti S, Montecucco C. Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. Arthritis Res Ther 2004; 6: R26472.
  • 71
    Nissinen R, Leirisalo-Repo M, Peltomaa R, Palosuo T, Vaarala O. Cytokine and chemokine receptor profile of peripheral blood mononuclear cells during treatment with infliximab in patients with active rheumatoid arthritis. Ann Rheum Dis 2004; 63: 6817.
  • 72
    Bos WH, Bartelds GM, Wolbink GJ, de Koning MH, van de Stadt RJ, van Schaardenburg D, et al. Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis. J Rheumatol 2008; 35: 19727.
  • 73
    Chen HA, Lin KC, Chen CH, Liao HT, Wang HP, Chang HN, et al. The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65: 359.
  • 74
    Aotsuka S, Okawa-Takatsuji M, Nagatani K, Nagashio C, Kano T, Nakajima K, et al. A retrospective study of the fluctuation in serum levels of anti-cyclic citrullinated peptide antibody in patients with rheumatoid arthritis. Clin Exp Rheumatol 2005; 23: 47581.
  • 75
    Kogure T, Tatsumi T, Fujinaga H, Niizawa A, Terasawa K. Insights to clinical use of serial determination in titers of cyclic citrullinated peptide autoantibodies. Mediators Inflamm 2007: 12367.
  • 76
    Nielen MM, van der Horst AR, van Schaardenburg D, van der Horst-Bruinsma IE, van de Stadt RJ, Aarden L, et al. Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis. Ann Rheum Dis 2005; 64: 1199204.
  • 77
    Kitahara K, Takagi K, Kusunoki Y, Nishio S, Nozaki T, Inomata H, et al. Clinical value of second- and third-generation assays of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis [letter]. Ann Rheum Dis 2008; 67: 105960.
  • 78
    Lutteri L, Malaise M, Chapelle JP. Comparison of second- and third-generation anti-cyclic citrullinated peptide antibodies assays for detecting rheumatoid arthritis. Clin Chim Acta 2007; 386: 7681.
  • 79
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 31524.
  • 80
    Reed GF, Lynn F, Meade BD. Use of coefficient of variation in assessing variability of quantitative assays. Clin Diagn Lab Immunol 2002; 9: 12359.
  • 81
    Van Gaalen FA, Visser H, Huizinga TW. A comparison of the diagnostic accuracy and prognostic value of the first and second anti-cyclic citrullinated peptides (CCP1 and CCP2) autoantibody tests for rheumatoid arthritis. Ann Rheum Dis 2005; 64: 15102.
  • 82
    Vander Cruyssen B, Nogueira L, van Praet J, Deforce D, Elewaut D, Serre G, et al. Do all anti-citrullinated protein/peptide antibody tests measure the same? Evaluation of discrepancy between anti-citrullinated protein/peptide antibody tests in patients with and without rheumatoid arthritis. Ann Rheum Dis 2008; 67: 5426.
  • 83
    Bizzaro N. Evaluation of the World Health Organization standard for anti-citrullinated peptide antibody assays [abstract]. Proceedings of the 6th International Conference on Autoimmunity; 2008 Sept 10–14, Porto, Portugal.
  • 84
    Avouac J, Gossec L, Dougados M. Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 2006; 65: 84551.
  • 85
    Korendowych E, Owen P, Ravindran J, Carmichael C, McHugh N. The clinical and genetic associations of anti-cyclic citrullinated peptide antibodies in psoriatic arthritis. Rheumatology (Oxford) 2005; 44: 105660.
  • 86
    Sghiri R, Bouagina E, Zaglaoui H, Mestiri H, Harzallah L, Harrabi I, et al. Diagnostic performances of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis. Rheumatol Int 2007; 27: 112530.
  • 87
    Ingegnoli F, Galbiati V, Zeni S, Meani L, Zahalkova L, Lubatti C, et al. Use of antibodies recognizing cyclic citrullinated peptide in the differential diagnosis of joint involvement in systemic sclerosis. Clin Rheumatol 2007; 26: 5104.
  • 88
    Alexiou I, Germenis A, Ziogas A, Theodoridou K, Sakkas LI. Diagnostic value of anti-cyclic citrullinated peptide antibodies in Greek patients with rheumatoid arthritis. BMC Musculoskelet Disord 2007; 8: 37.
  • 89
    Chan MT, Owen P, Dunphy J, Cox B, Carmichael C, Korendowych E, et al. Associations of erosive arthritis with anti-cyclic citrullinated peptide antibodies and MHC class II alleles in systemic lupus erythematosus. J Rheumatol 2008; 35: 7783.
  • 90
    Wu R, Shovman O, Zhang Y, Gilburd B, Zandman-Goddard G, Shoenfeld Y. Increased prevalence of anti-third generation cyclic citrullinated peptide antibodies in patients with rheumatoid arthritis and CREST syndrome. Clin Rev Allergy Immunol 2007; 32: 4756.
  • 91
    Van Rossum M, van Soesbergen R, de Kort S, ten Cate R, Zwinderman AH, de Jong B, et al. Anti-cyclic citrullinated peptide (anti-CCP) antibodies in children with juvenile idiopathic arthritis. J Rheumatol 2003; 30: 8258.
  • 92
    Kakumanu P, Yamagata H, Sobel ES, Reeves WH, Chan EK, Satoh M. Patients with pulmonary tuberculosis are frequently positive for anti–cyclic citrullinated peptide antibodies, but their sera also react with unmodified arginine-containing peptide. Arthritis Rheum 2008; 58: 157681.
  • 93
    Grootenboer-Mignot S, Nicaise-Roland P, Delaunay C, Meyer O, Chollet-Martin S, Labarre C. Second generation anti-cyclic citrullinated peptide (anti-CCP2) antibodies can replace other anti-filaggrin antibodies and improve rheumatoid arthritis diagnosis. Scand J Rheumatol 2004; 33: 21820.
  • 94
    Bizzaro N, Tonutti E, Tozzoli R, Villalta D. Analytical and diagnostic characteristics of 11 2nd- and 3rd-generation immunoenzymatic methods for the detection of antibodies to citrullinated proteins. Clin Chem 2007; 53: 152733.
  • 95
    Dejaco C, Klotz W, Larcher H, Duftner C, Schirmer M, Herold M. Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis. Arthritis Res Ther 2006; 8: R119.
  • 96
    Mathsson L, Mullazehi M, Wick MC, Sjoberg O, van Vollenhoven R, Klareskog L, et al. Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides. Arthritis Rheum 2008; 58: 3645.
  • 97
    Konnopka A, Conrad K, Baerwald C, Konig HH. Cost effectiveness of the determination of autoantibodies against cyclic citrullinated peptide in the early diagnosis of rheumatoid arthritis. Ann Rheum Dis 2008; 67: 1399405.
  • 98
    Kroot EJ, de Jong BA, van Leeuwen MA, Swinkels H, van den Hoogen FH, van ‘t Hof M, et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2000; 43: 18315.
  • 99
    Jansen AL, van der Horst-Bruinsma I, van Schaardenburg D, van de Stadt RJ, de Koning MH, Dijkmans BA. Rheumatoid factor and antibodies to cyclic citrullinated peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis. J Rheumatol 2002; 29: 20746.
  • 100
    Nell VP, Machold KP, Stamm TA, Eberl G, Heinzl H, Uffmann M, et al. Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann Rheum Dis 2005; 64: 17316.
  • 101
    Raza K, Breese M, Nightingale P, Kumar K, Potter T, Carruthers DM, et al. Predictive value of antibodies to cyclic citrullinated peptide in patients with very early inflammatory arthritis. J Rheumatol 2005; 32: 2318.
  • 102
    Matsui T, Shimada K, Ozawa N, Hayakawa H, Hagiwara F, Nakayama H, et al. Diagnostic utility of anti-cyclic citrullinated peptide antibodies for very early rheumatoid arthritis. J Rheumatol 2006; 33: 23907.
  • 103
    Ates A, Karaaslan Y, Aksaray S. Predictive value of antibodies to cyclic citrullinated peptide in patients with early arthritis. Clin Rheumatol 2007; 26: 499504.
  • 104
    Kudo-Tanaka E, Ohshima S, Ishii M, Mima T, Matsushita M, Azuma N, et al. Autoantibodies to cyclic citrullinated peptide 2 (CCP2) are superior to other potential diagnostic biomarkers for predicting rheumatoid arthritis in early undifferentiated arthritis. Clin Rheumatol 2007; 26: 162733.
  • 105
    Silveira IG, Burlingame RW, von Muhlen CA, Bender AL, Staub HL. Anti-CCP antibodies have more diagnostic impact than rheumatoid factor (RF) in a population tested for RF. Clin Rheumatol 2007; 26: 18839.
  • 106
    Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JM. How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum 2002; 46: 35765.
  • 107
    El Miedany Y, Youssef S, Mehanna AN, El Gaafary M. Development of a scoring system for assessment of outcome of early undifferentiated inflammatory synovitis. Joint Bone Spine 2008; 75: 15562.
  • 108
    Lakos G, Soos L, Fekete A, Szabo Z, Zeher M, Horvath IF, et al. Anti-cyclic citrullinated peptide antibody isotypes in rheumatoid arthritis: association with disease duration, rheumatoid factor production and the presence of shared epitope. Clin Exp Rheumatol 2008; 26: 25360.
  • 109
    Yamane T, Hashiramoto A, Tanaka Y, Tsumiyama K, Miura Y, Shiozawa K, et al. Easy and accurate diagnosis of rheumatoid arthritis using anti-cyclic citrullinated peptide 2 antibody, swollen joint count, and C-reactive protein/rheumatoid factor. J Rheumatol 2008; 35: 41420.
  • 110
    Nell-Duxneuner V, Machold K, Stamm T, Eberl G, Heinzl H, Hoefler E, et al. Autoantibody profiling in patients with very early rheumatoid arthritis: a follow-up study. Ann Rheum Dis 2009. E-pub ahead of print.
  • 111
    Liao KP, Batra KL, Chibnik L, Schur PH, Costenbader KH. Anti-CCP revised criteria for the classification of rheumatoid arthritis. Ann Rheum Dis 2008; 67: 155761.
  • 112
    Van der Helm-van Mil AH, le Cessie S, van Dongen H, Breedveld FC, Toes RE, Huizinga TW. A prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: how to guide individual treatment decisions. Arthritis Rheum 2007; 56: 43340.
  • 113
    Van der Helm-van Mil AH, Detert J, le Cessie S, Filer A, Bastian H, Burmester GR, et al. Validation of a prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: moving toward individualized treatment decision-making. Arthritis Rheum 2008; 58: 22417.
  • 114
    Thammanichanond D, Kunakorn M, Kitiwanwanich S, Attamasirikul K, Nantiruj K. Raising rheumatoid factor cutoff helps distinguish rheumatoid arthritis. Asian Pac J Allergy Immunol 2005; 23: 1658.
  • 115
    Kwok JS, Hui KH, Lee TL, Wong W, Lau YL, Wong RW, et al. Anti-cyclic citrullinated peptide: diagnostic and prognostic values in juvenile idiopathic arthritis and rheumatoid arthritis in a Chinese population. Scand J Rheumatol 2005; 34: 35966.
  • 116
    Kamali S, Polat NG, Kasapoglu E, Gul A, Ocal L, Aral O, et al. Anti-CCP and antikeratin antibodies in rheumatoid arthritis, primary Sjögren’s syndrome, and Wegener's granulomatosis. Clin Rheumatol 2005; 24: 6736.
  • 117
    Greiner A, Plischke H, Kellner H, Gruber R. Association of anti-cyclic citrullinated peptide antibodies, anti-citrullin antibodies, and IgM and IgA rheumatoid factors with serological parameters of disease activity in rheumatoid arthritis. Ann N Y Acad Sci 2005; 1050: 295303.
  • 118
    Fernandez-Suarez A, Reneses S, Wichmann I, Criado R, Nunez A. Efficacy of three ELISA measurements of anti-cyclic citrullinated peptide antibodies in the early diagnosis of rheumatoid arthritis. Clin Chem Lab Med 2005; 43: 12349.
  • 119
    Choi SW, Lim MK, Shin DH, Park JJ, Shim SC. Diagnostic performances of anti-cyclic citrullinated peptides antibody and antifilaggrin antibody in Korean patients with rheumatoid arthritis. J Korean Med Sci 2005; 20: 4738.
  • 120
    Girelli F, Foschi FG, Bedeschi E, Calderoni V, Stefanini GF, Martinelli MG. Is anti cyclic citrullinated peptide a useful laboratory test for the diagnosis of rheumatoid arthritis? Eur Ann Allergy Clin Immunol 2004; 36: 12730.
  • 121
    De Rycke L, Peene I, Hoffman IE, Kruithof E, Union A, Meheus L, et al. Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations. Ann Rheum Dis 2004; 63: 158793.
  • 122
    Das H, Atsumi T, Fukushima Y, Shibuya H, Ito K, Yamada Y, et al. Diagnostic value of antiagalactosyl IgG antibodies in rheumatoid arthritis. Clin Rheumatol 2004; 23: 21822.
  • 123
    Vallbracht I, Rieber J, Oppermann M, Forger F, Siebert U, Helmke K. Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis. Ann Rheum Dis 2004; 63: 107984.
  • 124
    Spiritus T, Verschueren P, Westhovens R, Bossuyt X. Diagnostic characteristics of a gelatin based Waaler-Rose assay (Serodia-RA) for the detection of rheumatoid factor. Ann Rheum Dis 2004; 63: 116971.
  • 125
    Soderlin MK, Kastbom A, Kautiainen H, Leirisalo-Repo M, Strandberg G, Skogh T. Antibodies against cyclic citrullinated peptide (CCP) and levels of cartilage oligomeric matrix protein (COMP) in very early arthritis: relation to diagnosis and disease activity. Scand J Rheumatol 2004; 33: 1858.
  • 126
    Lopez-Hoyos M, Ruiz de Alegria C, Blanco R, Crespo J, Pena M, Rodriguez-Valverde V, et al. Clinical utility of anti-CCP antibodies in the differential diagnosis of elderly-onset rheumatoid arthritis and polymyalgia rheumatica. Rheumatology (Oxford) 2004; 43: 6557.
  • 127
    Hitchon CA, Alex P, Erdile LB, Frank MB, Dozmorov I, Tang Y, et al. A distinct multicytokine profile is associated with anti-cyclical citrullinated peptide antibodies in patients with early untreated inflammatory arthritis. J Rheumatol 2004; 31: 233646.
  • 128
    Dubucquoi S, Solau-Gervais E, Lefranc D, Marguerie L, Sibilia J, Goetz J, et al. Evaluation of anti-citrullinated filaggrin antibodies as hallmarks for the diagnosis of rheumatic diseases. Ann Rheum Dis 2004; 63: 4159.
  • 129
    Bombardieri M, Alessandri C, Labbadia G, Iannuccelli C, Carlucci F, Riccieri V, et al. Role of anti-cyclic citrullinated peptide antibodies in discriminating patients with rheumatoid arthritis from patients with chronic hepatitis C infection-associated polyarticular involvement. Arthritis Res Ther 2004; 6: R13741.
  • 130
    Suzuki K, Sawada T, Murakami A, Matsui T, Tohma S, Nakazono K, et al. High diagnostic performance of ELISA detection of antibodies to citrullinated antigens in rheumatoid arthritis. Scand J Rheumatol 2003; 32: 197204.
  • 131
    Jansen LM, van Schaardenburg D, van der Horst-Bruinsma I, van der Stadt RJ, de Koning MH, Dijkmans BA. The predictive value of anti-cyclic citrullinated peptide antibodies in early arthritis. J Rheumatol 2003; 30: 16915.
  • 132
    Bizzaro N, Mazzanti G, Tonutti E, Villalta D, Tozzoli R. Diagnostic accuracy of the anti-citrulline antibody assay for rheumatoid arthritis. Clin Chem 2001; 47: 108993.
  • 133
    Aho K, Palosuo T, Lukka M, Kurki P, Isomaki H, Kautiainen H, et al. Antifilaggrin antibodies in recent-onset arthritis. Scand J Rheumatol 1999; 28: 1136.
  • 134
    Visser H, Gelinck LB, Kampfraath AH, Breedveld FC, Hazes JM. Diagnostic and prognostic characteristics of the enzyme linked immunosorbent rheumatoid factor assays in rheumatoid arthritis. Ann Rheum Dis 1996; 55: 15761.
  • 135
    De Bois MH, Arndt JW, Speyer I, Pauwels EK, Breedveld FC. Technetium-99m labeled human immunoglobulin scintigraphy predicts rheumatoid arthritis in patients with arthralgia. Scand J Rheumatol 1996; 25: 1558.
  • 136
    Cordonnier C, Meyer O, Palazzo E, de Bandt M, Elias A, Nicaise P, et al. Diagnostic value of anti-RA33 antibody, antikeratin antibody, antiperinuclear factor and antinuclear antibody in early rheumatoid arthritis: comparison with rheumatoid factor. Br J Rheumatol 1996; 35: 6204.
  • 137
    Saraux A, Valls I, Voisin V, Koreichi A, Baron D, Youinou P, et al. How useful are tests for rheumatoid factors, antiperinuclear factors, antikeratin antibody, and the HLA DR4 antigen for the diagnosis of rheumatoid arthritis? Rev Rhum Engl Ed 1995; 62: 1620.
  • 138
    Berthelot JM, Maugars Y, Audrain M, Youinou P, Prost A. Specificity of antiperinuclear factor for rheumatoid arthritis in rheumatoid factor-positive sera. Br J Rheumatol 1995; 34: 71620.
  • 139
    Gomes-Daudrix V, Sebbag M, Girbal E, Vincent C, Simon M, Rakotoarivony J, et al. Immunoblotting detection of so-called ‘antikeratin antibodies’: a new assay for the diagnosis of rheumatoid arthritis. Ann Rheum Dis 1994; 53: 73542.
  • 140
    Banchuin N, Janyapoon K, Sarntivijai S, Parivisutt L. Re-evaluation of ELISA and latex agglutination test for rheumatoid factor detection in the diagnosis of rheumatoid arthritis. Asian Pac J Allergy Immunol 1992; 10: 4754.
  • 141
    Young A, Sumar N, Bodman K, Goyal S, Sinclair H, Roitt I, et al. Agalactosyl IgG: an aid to differential diagnosis in early synovitis. Arthritis Rheum 1991; 34: 14259.
  • 142
    Davis P, Stein M. Evaluation of criteria for the classification of SLE in Zimbabwean patients. Br J Rheumatol 1989; 28: 5467.
  • 143
    Carpenter AB, Bartkowiak CD. Rheumatoid factors determined by fluorescence immunoassay: comparison with qualitative and quantitative methods. Clin Chem 1989; 35: 4646.
  • 144
    Winkles JW, Lunec J, Gray L. Automated enhanced latex agglutination assay for rheumatoid factors in serum. Clin Chem 1989; 35: 3037.
  • 145
    Vittecoq O, Salle V, Jouen-Beades F, Krzanowska K, Menard JF, Gayet A, et al. Autoantibodies to the 27 C-terminal amino acids of calpastatin are detected in a restricted set of connective tissue diseases and may be useful for diagnosis of rheumatoid arthritis in community cases of very early arthritis. Rheumatology (Oxford) 2001; 40: 112634.
  • 146
    Vasiliauskiene L, Wiik A, Hoier-Madsen M. Prevalence and clinical significance of antikeratin antibodies and other serological markers in Lithuanian patients with rheumatoid arthritis. Ann Rheum Dis 2001; 60: 45966.
  • 147
    Garcia-Berrocal B, Gonzalez C, Perez M, Navajo JA, Moreta I, Davila C, et al. Anti-cyclic citrullinated peptide autoantibodies in IgM rheumatoid factor-positive patients. Clin Chim Acta 2005; 354: 12330.
  • 148
    Snijders GF, Broeder AA, Bevers K, Jeurissen ME, van Eerd JE, van den Hoogen FH. Measurement characteristics of a new rapid anti-CCP2 test compared to the anti-CCP2 ELISA. Scand J Rheumatol 2008; 37: 1514.
  • 149
    Vossenaar ER, van Venrooij WJ. Citrullinated proteins: sparks that may ignite the fire in rheumatoid arthritis. Arthritis Res Ther 2004; 6: 10711.
  • 150
    Euro-Diagnostica. ELISA kit. 2008. URL: http://www.eurodiagnostica.com.
  • 151
    Inanc N, Dalkilic E, Kamali S, Kasapoglu-Gunal E, Elbir Y, Direskeneli H, et al. Anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis. Clin Rheumatol 2007; 26: 1723.
  • 152
    Alenius GM, Berglin E, Rantapaa Dahlqvist S. Antibodies against cyclic citrullinated peptide (CCP) in psoriatic patients with or without joint inflammation. Ann Rheum Dis 2006; 65: 398400.
  • 153
    Helliwell PS, Porter G, Taylor WJ. Polyarticular psoriatic arthritis is more like oligoarticular psoriatic arthritis, than rheumatoid arthritis. Ann Rheum Dis 2007; 66: 1137.
  • 154
    Nikolaisen C, Rekvig OP, Nossent HC. Diagnostic impact of contemporary biomarker assays for rheumatoid arthritis. Scand J Rheumatol 2007; 36: 97100.
  • 155
    Candia L, Marquez J, Gonzalez C, Santos AM, Londono J, Valle R, et al. Low frequency of anticyclic citrullinated peptide antibodies in psoriatic arthritis but not in cutaneous psoriasis. J Clin Rheumatol 2006; 12: 2269.
  • 156
    Sene D, Ghillani-Dalbin P, Limal N, Thibault V, van Boekel T, Piette JC, et al. Anti-cyclic citrullinated peptide antibodies in hepatitis C virus associated rheumatological manifestations and Sjögren's syndrome. Ann Rheum Dis 2006; 65: 3947.
  • 157
    Liu FC, Chao YC, Hou TY, Chen HC, Shyu RY, Hsieh TY, et al. Usefulness of anti-CCP antibodies in patients with hepatitis C virus infection with or without arthritis, rheumatoid factor, or cryoglobulinemia. Clin Rheumatol 2008; 27: 4637.
  • 158
    Lee SI, Yoo WH, Yun HJ, Kim DS, Lee HS, Choi SI, et al. Absence of antibody to cyclic citrullinated peptide in sera of non-arthritic patients with chronic hepatitis B virus infection. Clin Rheumatol 2007; 26: 107982.
  • 159
    Dewint P, Hoffman IE, Rogge S, Joos R, Union A, Dehoorne J, et al. Effect of age on prevalence of anticitrullinated protein/peptide antibodies in polyarticular juvenile idiopathic arthritis. Rheumatology (Oxford) 2006; 45: 2048.
  • 160
    Brunner J, Sitzmann FC. The diagnostic value of anti-cyclic citrullinated peptide (CCP) antibodies in children with juvenile idiopathic arthritis. Clin Exp Rheumatol 2006; 24: 44951.
  • 161
    Brunner JK, Sitzmann FC. Anticyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Mod Rheumatol 2006; 16: 3725.
  • 162
    Ceccato F, Roverano S, Barrionuevo A, Rillo O, Paira S. The role of anticyclic citrullinated peptide antibodies in the differential diagnosis of elderly-onset rheumatoid arthritis and polymyalgia rheumatica. Clin Rheumatol 2006; 25: 8547.
  • 163
    Elkayam O, Segal R, Lidgi M, Caspi D. Positive anti-cyclic citrullinated proteins and rheumatoid factor during active lung tuberculosis. Ann Rheum Dis 2006; 65: 11102.
  • 164
    Hill JA, Al-Bishri J, Gladman DD, Cairns E, Bell DA. Serum autoantibodies that bind citrullinated fibrinogen are frequently found in patients with rheumatoid arthritis. J Rheumatol 2006; 33: 21159.